Founded in April 2004 by Blake Paterson, M.D. and Alessio Fasano, M.D., Alba is focused on the discovery, development and commercialization of protein therapeutics to treat autoimmune, immune mediated and inflammatory diseases.  Dr. Fasano’s early discoveries describing zonula occluden toxin, its analogs and eukaryotic counterpart, their effect on paracelluar transport across epithelial and endothelial tight junctions and their role in immune mediated diseases serve as the foundation for a mucosal biology company focused on the role of barrier function in the etiology of disease.

Alba’s objective is to build a profitable biopharmaceutical company by discovering, developing and commercializing synthetic peptide and peptidomimetic drugs and vaccine and drug delivery adjuvants with a focus on specialty applications in the field of immunomodulation / inflammation (“IDI”).  The Company’s current product focus is based upon the modulation of cellular tight junctions to inhibit inappropriate barrier function and paracellular transport which leads to the propogation of autoimmune and inflammatory diseases.